Krenning EP - Search Results

1

Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.

Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP. Breeman WA, et al. Among authors: krenning ep. J Nucl Med. 2002 Dec;43(12):1650-6. J Nucl Med. 2002. PMID: 12468515 Free article.

2

New advances in peptide receptor radionuclide therapy.

de Jong M, Krenning E. de Jong M, et al. J Nucl Med. 2002 May;43(5):617-20. J Nucl Med. 2002. PMID: 11994523 Free article. No abstract available.

3

Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.

Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, Erion J, van Gameren A, Krenning E, de Jong M. Bernard B, et al. Cancer Biother Radiopharm. 2004 Apr;19(2):173-80. doi: 10.1089/108497804323071940. Cancer Biother Radiopharm. 2004. PMID: 15186597

4

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.

Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. Capello A, et al. Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1288-95. doi: 10.1007/s00259-005-1877-x. Epub 2005 Jul 15. Eur J Nucl Med Mol Imaging. 2005. PMID: 16021448

5

Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.

de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, Gekle M, Willnow TE, Walrand S, Jamar F, Pauwels S. de Jong M, et al. J Nucl Med. 2005 Oct;46(10):1696-700. J Nucl Med. 2005. PMID: 16204720 Free article.

6

Peptide-receptor radionuclide therapy for endocrine tumors.

van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. van Essen M, et al. Among authors: krenning ep. Nat Rev Endocrinol. 2009 Jul;5(7):382-93. doi: 10.1038/nrendo.2009.105. Epub 2009 Jun 2. Nat Rev Endocrinol. 2009. PMID: 19488074 Review.

7

Preclinical and clinical studies of peptide receptor radionuclide therapy.

Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, Valkema R, Kwekkeboom DJ, de Jong M. Pool SE, et al. Among authors: krenning ep. Semin Nucl Med. 2010 May;40(3):209-18. doi: 10.1053/j.semnuclmed.2009.12.001. Semin Nucl Med. 2010. PMID: 20350630 Review.

8

Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.

Melis M, de Swart J, de Visser M, Berndsen SC, Koelewijn S, Valkema R, Boerman OC, Krenning EP, de Jong M. Melis M, et al. Among authors: krenning ep. J Nucl Med. 2010 Dec;51(12):1962-8. doi: 10.2967/jnumed.110.080143. Epub 2010 Nov 15. J Nucl Med. 2010. PMID: 21078795 Free article.

9

Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, de Herder WW, Krenning EP. Kwekkeboom DJ, et al. Among authors: krenning ep. Endocrinol Metab Clin North Am. 2011 Mar;40(1):173-85, ix. doi: 10.1016/j.ecl.2010.12.003. Endocrinol Metab Clin North Am. 2011. PMID: 21349418 Review.

10

Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.

Kwekkeboom DJ, Krenning EP. Kwekkeboom DJ, et al. Among authors: krenning ep. Hematol Oncol Clin North Am. 2016 Feb;30(1):179-91. doi: 10.1016/j.hoc.2015.09.009. Hematol Oncol Clin North Am. 2016. PMID: 26614376 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

462 results

Search Page

Filters